Cargando…

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients

Detalles Bibliográficos
Autores principales:	van den Kerkhof, Tom, van Gils, Marit, Euler, Zelda, Verwer, Naomi, Sanders, Rogier, Schuitemaker, Hanneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236960/ http://dx.doi.org/10.1186/1742-4690-8-S2-P69

Ejemplares similares

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals
por: van den Kerkhof, TL, et al.
Publicado: (2012)

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
por: van den Kerkhof, Tom L G M, et al.
Publicado: (2013)

Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals
por: Euler, Zelda, et al.
Publicado: (2013)

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users
por: EULER, Zelda, et al.
Publicado: (2019)

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016)

Cross-reactive neutralizing activity in HIV-1 infected injecting drug users
por: Euler, Z, et al.
Publicado: (2012)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans
por: Malherbe, Delphine C., et al.
Publicado: (2013)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
por: Torrents de la Peña, Alba, et al.
Publicado: (2018)

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
por: van Schooten, Jelle, et al.
Publicado: (2022)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
por: Williams, Wilton B., et al.
Publicado: (2021)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Assessing immunogenicity barriers of the HIV-1 envelope trimer
por: Maliqi, Liridona, et al.
Publicado: (2023)

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques
por: Klasse, P. J., et al.
Publicado: (2018)

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics
por: Torrents de la Peña, Alba, et al.
Publicado: (2019)

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level
por: Bunnik, EM, et al.
Publicado: (2009)

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike
por: Derking, Ronald, et al.
Publicado: (2021)

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite
por: Nogal, Bartek, et al.
Publicado: (2020)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
por: van der Velden, Yme U., et al.
Publicado: (2020)

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL
por: Isik, Gözde, et al.
Publicado: (2014)

Clinical significance of HIV-1 coreceptor usage
por: Schuitemaker, Hanneke, et al.
Publicado: (2011)

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
por: Medina-Ramírez, Max, et al.
Publicado: (2017)

Signatures of V(H)1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins
por: Capella-Pujol, Joan, et al.
Publicado: (2023)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
por: Brouwer, Philip J.M., et al.
Publicado: (2019)

Natural infection as a blueprint for rational HIV vaccine design
por: van Haaren, Marlies M., et al.
Publicado: (2016)

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions
por: Seabright, Gemma E., et al.
Publicado: (2020)

Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers
por: de Taeye, Steven W., et al.
Publicado: (2018)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

Determinants of Tenascin-C and HIV-1 envelope binding and neutralization
por: Mangan, Riley J., et al.
Publicado: (2019)

Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review
por: Derking, Ronald, et al.
Publicado: (2021)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers
por: del Moral-Sánchez, Iván, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_heqhuf2pn6ufr82bic8f25st1n